Table 3.

Carotid artery preconstricted diameter (μm) and percentage preconstriction (%) prior to dose response to ACh with and without l-NAME in the absence (CNT) or presence of pre-treatment with TEMPOL (TMP) or apocynin (APO) (n= 4–10 per group) in young (Y) and old (O) cage control (CC) and voluntary wheel running (VR) mice

		YCC		OCC		YVR		OVR
		ACh alone	ACh +l-NAME	ACh alone	ACh +l-NAME	ACh alone	ACh +l-NAME	ACh alone	ACh +l-NAME
μm	CNT	334 ± 4	292 ± 10#	362 ± 10*	318 ± 14#	338 ± 13	293 ± 6#	355 ± 11	323 ± 11
	TMP	354 ± 7‡	334 ± 11‡	384 ± 6*	371 ± 7*‡	360 ± 6	320 ± 9#‡	369 ± 5	349 ± 9
	APO	331 ± 7	330 ± 9‡	362 ± 11*	314 ± 14#	306 ± 15	300 ± 15	350 ± 6	325 ± 5#
%	CNT	17.1 ± 1.2	28.4 ± 2.8#	16.3 ± 1.7	26.6 ± 2.7#	17.7 ± 3.3	28.1 ± 2.6	15.5 ± 2.6	23.2 ± 2.6
	TMP	13.6 ± 1.7	18.9 ± 2.4‡	13.8 ± 1.2	15.8 ± 1.0‡	13.3 ± 1.9	23.0 ± 2.3#	13.2 ± 1.4	17.7 ± 2.3
	APO	21.0 ± 2.2	21.7 ± 2.7	18.6 ± 2.9	29.2 ± 3.5#	21.1 ± 3.8	20.6 ± 3.7	14.3 ± 2.9	20.2 ± 2.9

^*P < 0.05 vs. YCC within treatments;

^†P < 0.05 vs. OCC within treatments;

^#P < 0.05 vs. ACh after l-NAME within the same group and treatment;

^‡P < 0.05 vs. CNT treatment within dose response.